Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Tuesday, 19 September 2017

Nicox to present at the Cantor Fitzgerald 2017 Global Healthcare Conference

NICOX    


 

Nicox to present at the Cantor Fitzgerald 2017 Global Healthcare Conference

 

September 19, 2017

Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Michele Garufi, Chairman and Chief Executive Officer of Nicox, will present at the Cantor Fitzgerald 2017 Global Healthcare Conference on Tuesday, September 26th, 2017 at 1:05 p.m. Eastern Time.  The conference is being held at the InterContinental New York Barclay Hotel.

The presentation will be available on Nicox website (www.nicox.com) in "Presentations & Events".

 

About Nicox

Nicox S.A. is an international ophthalmic company developing innovative solutions to help maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel drug candidates that target multiple ophthalmic conditions, including glaucoma. Nicox currently has one product at the review stage with the U.S. Food and Drug Administration (FDA), VYZULTATM (ophthalmic solution of latanoprostene bunod), 0.024%, licensed worldwide to Bausch + Lomb, and one product with an approved NDA, ZERVIATETM (cetirizine ophthalmic solution) 0.24%.  In addition its promising drug-candidate pipeline includes a next-generation of stand-alone nitric-oxide donors and exploratory novel NO-donating compounds, as well as repurposing of existing molecules with the potential to offer novel approaches to treat a range of ophthalmic conditions. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co   Hugo Solvet                 Paris, France

Invest Securities          Martial Descoutures    Paris, France

Gilbert Dupont             Damien Choplain        Paris, France

 

 

The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Upcoming financial and business conferences

 

November 23-24           Actionaria                                                                                           Paris, France 

Contacts

Nicox

Gavin Spencer,

Executive Vice President Corporate Development
T +33 (0)4 97 24 53 00

communications@nicox.com

Investor Relations

Europe
Nicox

Corporate Communications Department

T +33 (0)4 97 24 53 00

communications@nicox.com

 

Media Relations
United Kingdom
Jonathan Birt

T +44 7860 361 746

jonathan.birt@ymail.com

United States
Argot Partners

Melissa Forst

T +1 (212) 600-1902

melissa@argotpartners.com

France
NewCap

Nicolas Merigeau

T +33 (0)1 44 71 94 98

nicox@newcap.eu

 

United States
Argot Partners

Eliza Schleifstein

T +1 (917) 763-8106

eliza@argotpartners.com

Disclaimer

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Nicox S.A.

Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

 





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: NICOX, Drakkar D, 2450 route des Dolines BP 313, Sophia Antipolis, Valbonne FR-06560, France
If you would like to unsubscribe and stop receiving these e-mails click here.